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HCV Proteins
 There are two UTRs located at the 5’and 3’ termini 
called cis-active RNA elements which are essential for 
protein translation. The virus translation is cap-independent 
by IRES located at the 5’_UTR. A single precursor 
polyprotein is approximately 3010 amino acids, (NH2-C-
E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH) 
be cleaved into at least 10 different proteins. Structural 
proteins Core, E1, E2 and p7 are released from the 
polyprotein after cleavage by cellular proteases and some 
non-structural proteins such as NS2, NS3, NS4A, have 
been produced by virus-encoded proteases (de Vicente 
et al., 2009; Chatel-Chaix, et al., 2011). Core protein 
consists of first 191 amino acids and can be divided into 
three domains. Domain 1 (amino acids 1-117), Domain 2 
(amino acids 118-174) is more hydrophobic and Domain 
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Abstract
 Background: Hepatitis C virus (HCV) causes acute and chronic human hepatitis infection and as such is 
an important global health problem. HCV was discovered in the USA in 1989 and it is now known that three 
to four million people are infected every year. The WHO estimates that 3 percent of the 180 million people 
worldwide are chronically infected. Humans are the natural hosts of HCV and this virus can eventually leads 
to permanent liver damage and carcinoma. HCV is a member of the Flaviviridae family and Hepacivirus genus. 
The diameter of the virus is about 50-60 nm and the virion containing a single-stranded positive RNA with 
approximately 10,000 nucleotides in length and consists of one ORF which is encapsulated by an external lipid 
envelope and icosahedral capsid. HCV is a heterogeneous virus, classified into 6 genotypes and more than 50 
subtypes. Because of the genome variability, nucleotide sequences of genotypes differ by approximately 31-34%, 
and by 20-23% among subtypes. The quasispecies of mixed virus populations make survival advantage for virus 
to create multiple variant genomes and a high rate of generation of variants to allow rapid selection of mutants 
for new environmental conditions. Direct contact with infected blood and blood products, sexual relationships 
and availability of injectable drugs have had remarkable effects on HCV epidemiology. Hundreds of thousands 
of people die each year from hepatitis and liver cancer caused by HCV virus infection. Approximately 80% of 
patients with acute hepatitis C progress into a chronic disease state leading to serious hepatic disorders, 10-20% 
of which develop chronic liver cirrhosis and hepatocellular carcinoma. The incubation period of HCV is 6-8 
weeks and the infection is often asymptomatic so it is very hard to detect at early stages, making early treatment 
very difficult. Therefore, hepatitis C is called a “silent disease”. Neutralizing antibodies are produced against 
several HCV proteins during infection but the virus mutates to escape from antibodies. Some patients with 
chronic hepatitis C may have some symptoms such as fatigue, muscle aches, nausea and pain. Autoimmune and 
immunecomplex-mediated diseases have also been reported with chronic HCV infection.
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3 (amino acids 175-191) is highly hydrophobic (Honda 
et al., 2000). Domain 1 of Core protein can bind viral 
RNA. Core protein is involved in hepatocarcinogenesis 
and associated with the endoplasmic reticulum (ER), lipid 
droplets, mitochondria and the nucleus and also interacts 
with numerous cellular proteins and affects host cell 
functions such as gene transcription, lipid metabolism, 
apoptosis and cell signaling pathways (Counihan et al., 
2011). Alternate reading frame proteins or ARFPs includes 
(1) frame shifting (2) form transcriptional slippage, or 
(3) from internal initiation in the +1 open reading frame 
(ORF) of the core protein coding sequence (Hsieh et al., 
2012). Two “envelop proteins” E1 and E2 are highly 
glycosylated and play an important role in cell entry. 
E2 glycoprotein has 11 N-glycosylation sites acts as the 
receptor binding and E1glycoprotein contains 4-5 N-linked 
glycans serves as the fusogenic subunit. E1 protein extends 
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from 192-383aa and E2 from 384-746 aa, have molecular 
weights of 33-35 and 70-72 kDa, respectively. E1, E2 
glycoproteins are processed by Golgi glycosidases and 
glycosyltransferases (Fouad et al., 2012). E1 is able to 
adopt a polytopic and has a heterodimeric noncovalent 
association with E2. E1 also interacts with Core, and 
this interaction being dependent on oligomerization of 
Core. According to E2 function, E2 can bind especially 
to immune receptor CD81 (Cluster of Differentiation 81) 
as a main receptor for this virus, high density lipoprotein 
(HDL) and also scavenger receptor (type B class 1) 
protein (SRB-1) but the interaction of E2 protein due to 
viral entry with Mannose binding proteins (DC-SIGN and 
L-SIGN) is not known. E2 has two hypervariable regions 
(HVR) which are under selection for mutation and they 
are targets for neutralizing antibodies (Fujiwara et al., 
2012). The genetic heterogeneity of the HVR helps virus 
to evade the immune system. P7 is a membrane-spanning 
protein and with two transmembrane domains (TMDs) 
connected to ER lumen. This protein is 63-amino acid 
polypeptide located between HCV E2 and NS2 genes 
(Gupta et al., 2012). The cleavage of p7 is mediated by 
the ER signal peptidases between at the E2/p7 and p7/
NS2 sites. P7 has been shown to be essential for virus 
particle assembly and release of virions. HCV P7 form is 
like ion channels, plays an essential role in virus infection 
and this form is similar to those groups of proteins called 
viroporins (Huang et al., 2010). NS2 interacts with itself 
is a 21-23 kDa transmembrane protein and is essential for 
viral replication cycle in vitro or in vivo. N-terminal of 
NS2 contains three or four transmembrane helices which 
insert into the ER and the C-terminal part of NS2 play an 
important role in NS2/3 auto protease activity together 
with the NS3 called metalloproteases. The C terminal 
domain of NS2 has two composite active sites. Moreover 
NS2 interact with other non structural proteins and to be 
involved in virus particle assembly (Kim et al., 2007). NS3 
is a member of the superfamily 2 DExH/D-box helicases 
with multifunctional activity. It is 67 kDa with a serine 
protease in N-terminal, RNA helicase in C-terminal and 
NTPase activities. Serine protease catalytic activity is due 
to three amino acid residues His-1083, Asp-1107 and Ser-
1165 with its cofactor NS4A involved in cleavage between 
NS3/4A, NS4A/4B, NS4B/5A and NS5A/5B. NS3 protein 
also interacts with the catalytic subunit of protein kinase A 
(PKA) and deregulates intracellular signaling. NS3 serine 
protease suppress innate cellular host defense by inhibition 
of RIG-I and TLR3 signalling (Yang et al., 2006; Wu et 
al., 2008; de Vicente et al., 2009). The NTPase/helicase 
domain is in the C-terminal of the NS3 protein which is 
responsible for RNA and DNA unwinding activity in a 
3’-5’ direction and the NS3 helicase is modulated by this 
interaction with NS5B polymeras. Other posttranslational 
modifications such as phosphorylation and acetylation are 
reported in NS3 (Ma et al., 2008).
 Non structural protein 4A acts as a cofactor for NS3 
protein and this interaction is mediated between residues 
within the core of NS3 and the C-terminus of NS4A. 
NS4A has 54 amino acids and it was proposed that last 
20 amino acids anchor the complex on the ER membrane. 
NS4A is also required for the phosphorylation of the 
centre of NS5A (amino acids 2135-2139) (Yamanaka 
et al., 2002; Wu et al., 2008). Non structural protein 
4B is a small hydrophobic 27 kDa polypeptide. The 
C-terminus and N-terminus have a topology associated 
with membranes and ER lumen by co-localization with 
other non-structural proteins in the ER. NS4B interacts 
directly with NS4A and indirectly with NS3 and NS5A 
but failed to show cytopathic or oncogenic effects in 
the livers of transgenic mice (Wu et al., 2008). NS5A is 
phosphorylated (56 kDa) and hyperphosphorylated (58 
kDa) and this hydrophilic phosphoprotein has an important 
role in viral replication, modulation of cell signaling and 
interferon response. N-terminal of NS5 has an essential 
zinc motif, which play an important role in structural 
integrity. NS5A contains a region (amino acids 237−276) 
called interferon-a sensitivity-determining region (ISDR) 
which interacts directly with an IFN-a stimulated gene 
product, PKR protein kinase which is activated by binding 
to doublestranded RNA and modulates the IFN response 
(Tong and Malcolm, 2006; de Vicente et al., 2009). The 
NS5B is 65 kDa protein acts as RNA dependent RNA 
polymerase with a typical ‘right hand’ polymerase shape 
(finger, palm, and thumb sub domains) plays a role in new 
RNA synthesis and initiates synthesis of complementary 
negative-strand RNA using the HCV genome (positive 
polarity) as a template (Pratt et al., 2005).
HCV Epidemiology
 HCV is divided into six major genotypes and more 
than 80 subtypes. 30-50% variation among genotypes 
and 15-30% among subtypes while 1-5% variation 
in nucleotide sequence from a single HCV infected 
patient. The hypervariable region is in E1 and E2 and the 
lowest variability is found in the 5’ untraslated region 
(UTR) containing RNA secondary structures which 
are required for replication and translation functions. 
The lack of proofreading activity of RNA-dependent 
RNA polymerase causes sequence variability and the 
nucleotide misincorporation rate is approximately 10-3 
base substitutions per genome site per year (Bhatti et 
al., 1995; Fujiwara et al., 2012). All HCV genotypes are 
pathogenic and hepatotropic and influence on the rate of 
progression to cirrhosis and HCC. According to World 
Health Organization data, 3% of the human population, 
Figure 1. Genome and Proteins Structure for Hepatitis 
C Virus
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(approximately 170 million people), is infected with HCV 
and the prevalence of chronic HCV is 0.1-26% and varies 
in different regions (Bassyouni et al., 2012). There are 
geographic and temporal differences in the patterns of 
HCV infection. Different countries, including the United 
States, Australia, Turkey, Spain, Italy, and Japan, the 
average prevalences of HCV infection is (1.0-1.9%), but 
have different patterns of age-specific prevalence (Carreno 
et al., 2012). Genotype 1 is the most common type and 
presents 40-80% of HCV chronic infection (Roffi et al., 
1998). In USA Genotype 1 is common, but in Europe and 
Japan genotypes 2 and 3 are more common. In Egypt and 
the Middle East Genotype 4 is the most common genotype 
and in southern Africa genotype 5 is most prevalent, 
genotype 6 is in Hong Kong and other countries of 
south eastern Asia; genotypes 4, 5 and 6 are rarely found 
outside of those African or Asian regions (Wang et al., 
2009). About 80% of patients in Poland are infected with 
genotype 1b. Genotype 3 is most frequent in India, Nepal 
and Pakistan. Genotype 4 is a common genotype in Africa 
and the Middle East. Genotypes 1a, 1b and 3a are the most 
prevalent genotypes in Iran and in Pakistan the major HCV 
genotype is 3a. The prevalence rate is: in Africa 5.3%, 
in the Eastern Mediterranean 4.6%, in the West Pacific 
3.9%, in Southeast Asia 2.15%, in the Americas 1.7%, in 
Europe 1.03%. For many developing countries, including 
Iran HCV prevalence are not available. A recent study 
on blood donors indicated a seroprevalence of 0.13% 
during the period of 2004-2007 and the male to female 
ratio 10:1 in such reports. Prevalence of HCV in Iran is as 
high as 11-25% for patients on hemodialysis and11-52% 
for intravenous drug abusers and 15-76% for hemophilia 
and thalassemia patients (Mizui et al., 1994; Gelberg et 
al., 2012; Kamili et al., 2012; Klevens et al., 2012).
HCV Entry into the Host Cell 
 HCV entry is the first step in a virus life-cycle which is 
a slow and complex interaction between a receptor on the 
cell surface and a viral attachment protein. HCV receptors 
or coreceptors in host cell are glycosaminoglycans, CD81, 
scavenger receptor class B type I (SRBI), members of the 
claudin family (CLDN1, 6 and 9) and mannose-binding 
lectins DC-SIGN and L-SIGN and their interaction is 
associated to HCV virion proteins (Dreux, Peitschmann et 
al., 2006). Initial attachment is with GAGs and the LDL-R 
and followed by interaction with SR-BI and CD81 with 
binding of HCV E2 with high affinity to the large external 
loop of CD81 and CLDN1. HCV may enter to the cell by 
binding to low-density lipoprotein (LDL) receptors (Piver 
et al., 2010). The role of E1 is less clear but the presence of 
hydrophobic amino acids tentatively called the E1 fusion 
peptide, displaying similarities to the fusion peptides and 
suggests that E1 is involved in membrane fusion. E1 and 
E2 form heterodimers that represent the native form of 
HCV envelope (Tan et al., 2003; Steinmann et al., 2004; 
Zhang et al., 2008; Velazquez et al., 2012; Ye et al., 2012; 
Zeng et al. 2012).
Transcription, Replication and Translation
 After virus internalizing, nucleocapsid is released 
into the cytoplasm and the virus is decapitated. Then 
genomic HCV RNA is used for translation and replication 
in the cytoplasm. Translation of the viral RNA is cap-
independent mechanism and HCV IRES binds to the 40S 
ribosome subunit (Ye et al., 2012). The single polyprotein 
is translated at the rough endoplasmic reticulum (ER) and 
cleaved co- and posttranslational by cellular and viral 
proteases to produce structural and non structural proteins. 
A proteinase and NTPase/helicase activity is found NS3 
and this protein has some corporation with NS4A and NS5 
for their actions (Ma et al., 2008).
 RNA-dependent RNA polymerase replicates the 
genome by the synthesis of negative strand RNA. Negative 
strand RNA serves as a template for the synthesis of 
positive strands. NS5B RdRp is the key player catalysing 
the synthesis of minus and plus strand RNA and NS5A 
is involved in regulation of replication. Replication and 
post-translational processing take place in a membrane 
located in close perinuclear membranes. HCV E proteins 
are in the ER compartment and the viral nucleocapsids 
acquire their envelope by budding through ER membranes. 
Genome encapsidation take place in ER and nucleocapsids 
get envelop and be matured in Golgi apparatus before 
produced virions are released in the pericellular space by 
exocytosis (Bhatti et al., 1995; Pan et al., 2007; Huang et 
al., 2010; Nakabayashi 2012).
HCV Transmission
Intravenous drug use
 Transmission of Hepatitis C virus is associated with 
intravenous and percutaneous drug and using needle. Most 
countries with a young population have reported HCV 
Figure 2. Distribution of HCV Genotypes in the World Figure 3. HCV Entry to the Host Cell and Replication
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transmission with intravenous drug using as the main 
cause of virus spread and the interesting point is many of 
these intravenous drug users do not know they have been 
infected. In the District Buner study in Pakistan, all 751 
anti-HCV patients had a history of injections. Another 
study in London, England took 428 intravenous drug 
users and found that 44% had antibodies to hepatitis C. 
Many studies in Iran reported that the rate of intravenous 
drug users (IDUs) with HCV infection is between 38% 
and 47% (Bevilacqua et al., 2009).
Blood Transfusions
 HCV infection may result from blood transfusion 
and blood products however, with improved screening, 
HCV transmission through transfusions has decreased 
in most developed countries. In the US, incidence of 
post-transfusion hepatitis C dropped from 3.84-0.57% 
per patient after HCV screening in 1990 (Gunson et al., 
2003). In England, the frequency HCV infected donations 
dropped from 1 in 520,000 (1993-98) to 1 in 30 million 
(1999-2001) when donations were tested for HCV RNA. 
There are approximately 105-107 viral particles in 1 ml 
of blood of an infected patient with the chronic form 
of the disease (Ruzzenenti et al., 2000; Januszkiewicz-
Lewandowska et al., 2003).
Sexual activity
 Sexual transmission of HCV reported in 2-27% of 
patients and the prostitutes, intravenous drug users and 
homosexuals are being the most commonly affected. A 
study among spouses in Egypt, it reported that wife to 
husband transmission was 34% with detectable HCV 
RNA and 10% without detectable HCV RNA among 
women and transmission of husband to wife was 3%. 
Sexual transmission of HCV is still rare but it is higher 
in high-risk sexual activity (Zeremski et al., 2012).
Hemodialysis
 Dialysis patients have a higher rate of HCV infection 
and the rate of seroconversion among hemodialysis 
patients with no other risk factors has been reported 
1.38-1.9% per year. The prevalence of HCV infection 
in Iranian hemophilic patients is from 15.6% in Fars, a 
southern district of Iran to 76.7%, in North-West of Iran 
and the prevalence rate of thalassemic patients with HCV 
infection is between 15.7% and 63.8%. Prevalence rates 
of HCV in Ireland (1.7%), in Europe 20-30% and in Saudi 
Arabia showed to be 9.24% (Ruzzenenti et al., 2000). 
Transmission of the HCV virus to hemodialysis patients 
happens with possible risk factors such as  disinfect 
devices between patients, sharing of vials for infusions, 
lack of sterile technique and poor cleaning of dialysis 
machines (Januszkiewicz-Lewandowska et al., 2003). 
Special Populations
 Hemophiliacs and patients receiving hemodialysis are 
2 groups of patients prone to the infection and 50-90% 
of hemophiliacs patients are infected with HCV and this 
are caused by numerous blood transfusions and blood 
product infusions. For organ transplant, 50% of patient’s 
transmission of the virus occurs when a donor is an HCV 
infected person and also it may occur during invasive 
diagnostic procedures (e.g. organ biopsies, endoscopic 
examination). In Italy the prevalence was reported 33.3% 
among kidney transplants and most of these kidneys 
transplant patients have done dialysis as well. The HCV 
infection can be acquired through perinatal exposure and it 
is not clear that the disease could occur during pregnancy, 
at birth, after delivery or while breastfeeding (Delamare 
et al., 1999; Huët and Dabis, 2000; Januszkiewicz-
Lewandowska et al., 2003; Quesnel-Vallières et al., 2008; 
Bevilacqua et al., 2009; Jorgensen et al., 2012).
HCV Evasion Strategy 
 HCV evades from innate and adaptive immune 
responses in several ways. NS3/4A proteins of HCV can 
block RIG-1 activation and translation of IRF-3 and impair 
the interferon signaling pathway. JAK/STAT pathway is 
interfered with HCV core protein by activating SOCS-3 
which is a JAK-STAT signaling inhibitor and increases the 
degradation of STAT1 (Iken et al., 2006). Protein kinase 
receptor (PKR) activity can be blocked by HCV E2 protein 
and also E2 inhibits cytotoxicity or IFN production by 
NK cells when E2 crosslinks the HCV receptor CD81 
(Merquiol et al., 2010). HCV escapes from antiviral 
action of interferon with NS5A. Interferon sensitive region 
(ISDR) in NS5A plays an important role in response of 
interferon therapy. Moreover, protein kinase receptor is 
blocked and PKR expression is down-regulated by NS5A 
and also NS5A induces IL-8 which inhibits the antiviral 
actions of IFN (Nguyen et al., 2006). HCV escapes 
from adaptive immune response with several different 
mechanisms. One of the major HCV virus evasion 
strategies is mutational escape of HCV which is due to 
lack of proofreading activity of RNA polymerase and high 
replication rate (1012 virions per day) of HCV and also 
HCV can escape from B cell with Sequence changes in 
Figure 4. Frequency of HCV Transmission Routs Figure 5. Immune Response to HCV Infection
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Figure 6. Treatment Strategy of HCV Infection
the hypervariable region of the E2 envelope glycoprotein 
(Cao et al., 1996; Yoo et al., 2010).
HCV Infection Diagnostics
Serological assays
The first generation of anti-HCV test widely used 
for c100-3 epitope from the nonstructural NS4 region. 
Third-generation enzyme immunoassays (EIAs) with 99% 
specificity including core, NS3, NS4, and NS5 regions 
of the HCV genome can be used to detect antibodies 
in plasma or serum against various HCV epitopes and 
the optical density (OD) ratio of the reaction shows the 
amount of antibodies in the serum or plasma samples (Cao 
et al., 1996; Coppola et al., 2009). Moreover, Immunoblot 
tests are clinically obsolete given the good performance 
of third-generation anti-HCV EIAs. An HCV diagnosis 
can be confirmed with Recombinant immunoblot assays 
(RIBA) and the second, third-generation RIBA HCV strip 
immunoblot assays (SIAs) (HCV 2.0 and 3.0 SIAs) are 
established methods and since 1992, the third-generation 
RIBA system (RIBA HCV 3.0 SIA) been widely used in 
Europe.  Serological determination of the HCV genotype 
can be reported by seeking for antibodies directed to 
genotype-specific HCV epitopes with a competitive EIA 
(Masalova et al., 1998; Lee et al., 2007; Schmeding et al., 
2010; Kamili et al., 2012).
Molecular diagnosis
Qualitative HCV RNA detection.
 The HCV RNA in the plasma in active infection can 
be detected 1-3 weeks post-exposure.Qualitative assays 
are based on target amplification using either polymerase 
chain reaction (PCR), “real-time” PCR or “transcription-
mediated amplification” (TMA). After HCV RNA 
extraction and cDNA synthesis, Double-stranded DNA 
copies of HCV genome are synthesized in PCR assays, 
whereas single-stranded RNA copies are generated in 
TMA. In “real-time” PCR, the number of fluorescent 
signals per cycle is proportional to the amount of HCV 
RNA in the sample (Abacioğlu et al., 1996; Bossi and 
Galli, 2004).
HCV RNA Quantification
 The World Health Organization (WHO) has established 
an international standard for universal standardization of 
HCV RNA quantification units (IU) which is used in all 
of the commercial HCV RNA quantitative assays. HCV 
RNA quantity can be used in competitive PCR, real-time 
PCR and branched DNA (bDNA) assay. bDNA method 
uses solid phase oligonucleotide probes that capture 
target RNA, after hybridization of branched secondary 
probe, the bDNA bind to enzyme conjugated probes 
and after substrate is added the chemiluminescence 
produced is proportional to the amount of target RNA. 
Five standardized assays are commercially available, two 
of them are based on competitive PCR [Cobas Amplicor 
HCV Monitor® v2.0 (Roche Molecular Systems), and LCx 
HCV RNA Quantitative Assay (Abbott Laboratories)]; 
one is based on bDNA technology [Versant® HCV RNA 
3.0 Assay (Siemens)]; and two are based on real-time 
PCR amplification [Cobas TaqMan HCV Test and Abbott 
RealTimeTM HCV assay (Abbott Diagnostics)] (Bossi 
and Galli, 2004; Tanaka et al., 2004; Mavromara et al., 
2005). 
HCV genotype detection 
HCV genotype determination method is direct 
sequencing of the 5’ UTR, NS5B or E1 regions of HCV 
genome and alignment with prototype sequences and 
phylogenetic analysis and using various commercial kits 
for direct sequence analysis of the 5’ noncoding region 
(Trugene® 5’NC HCV Genotyping Kit, Bayer Health Care) 
or reverse hybridization analysis using genotype-specific 
probes located in the 5’ noncoding region commercialized 
as INNO-LiPA HCV, Innogenetics, Ghent, Belgium, or 
Versant® HCV Genotyping Assay, Bayer HealthCare)
(Abacioğlu et al., 1996; Albertoni et al., 2010; Ciotti 
et al., 2010). For HCV genotyping base on Serology 
techniques, the different genotypes can be determined by 
antibodies irected to genotype-specific HCV epitopes 
with a competitive EIA. In restriction fragment length 
polymorphism (RFLP) analysis, a certain region of the 
HCV genome is amplified with universal primers and 
restriction enzyme recognition sites present in the DNA 
fragment usually show type-specific distribution. Thus, 
vary lengths of restriction fragments are created after 
cutting the PCR fragment with restriction endonucleases. 
The mobility of these fragments in the gel shows the 
approximate lengths of the restricted fragments and 
identifies the genotype (Monis et al., ????; Mizui et al., 
1994; Mangia et al., 1997; Zheng et al., 2003; Safi et al., 
2012).
Liver Biopsy
 Serum alanine aminotransferase (ALT) measurements, 
when combined with Liver biopsy, can be useful in 
determining the virus activity in liver. So the stage of 
fibrosis and liver biopsy is recommended for treatment to 
know disease stage and distinguish other forms of liver 
disease. Immunohistochemistry with the TORDJI-22 
monoclonal antibody is a very specific and sensitive 
diagnostic test for hepatitis C virus in fixed liver tissues. 
Increasing of Serum hyaluronic acid (HA) during 
fibrogenesis is a useful marker in chronic HCV patients 
in and can be monitored at progressive fibrosis (Erensoy, 
2001; Al Swaff, 2012; Carreno et al., 2012).
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Protective Immunity to HCV
HCV clearance could be related to host genetic 
background such as HLA types, cytokine and chemokine 
expression (e.g., IL-10, IL-28B, and CCR5). Many 
studies published recently HCV clearance is associated 
with HLA-B27 allele in MHC class I locus and MHC 
class I is associated with CD8+ T cells, so this shows 
that cytotoxic T is very important in HCV eradication. 
Many studies reported that when patients with chronic 
HCV infection were investigated, the lack of cytotoxicity 
in CD8+T cells against HCV epitopes was observed and 
patients with resolved HCV infection contained stronger 
CD8+ T cell responses (Feinstone et al., 2012). CD4+ T 
cells are vital in HCV recovery and important in adaptive 
immunity. For example; CD4+ T helper cells are effective 
in B cells and CD8+ T cells functions or CD4+ T cells 
activity induce IL-2 and IFN-γ secretion that seemed to 
correlate with HCV clearance during acute HCV infection 
and also CD4+ T cells are specific to many different HCV 
epitopes in chronic infected individuals (van de Laar et 
al., 2010). Neutralizing antibodies are responsible for 
immune protection against HCV infection. If E1 and 
E2 proteins are present on the surface of HCV virions, 
specific antibodies, mostly IgG isotype, have the capacity 
to neutralize them. Generally with third generation of 
EIA anti-HCV assays, anti-HCV antibodies to HCV 
core, NS3, NS4, and NS5 proteins can be measured 
(Alter et al., 2011). Different studies have showed that 
the polymorphism at the upstream of IL28B is associated 
strongly with sustained virological response and Patients 
who express more IL28 mRNA have a better response to 
standard IFN therapy. IFN-λ3 together with IFN-λ1 (IL-
29) and IFN-λ2 (IL-28B), have a complex connection with 
IL-28Rα and IL-10Rβ to produce JAK/STAT pathway, 
has an anti-viral effects like interferon type I (IFN-α and 
IFN-β) (Eisenbach et al., 2006; Bassyouni et al., 2012; 
Zeremski et al., 2012).
Management of Antiviral Therapy 
The presence of HCV RNA in the absence of anti-
HCV antibodie indicates the acute HCV infection, 
so patients with acute hepatitis C should be tested 
for anti-HCV antibodies which will be confirmed by 
seroconversion a few days later and HCV RNA with a 
lower limit of detection of 50 IU/mL or less with sensitive 
techniques(Ampurdanés et al., 1996). If both anti-HCV 
antibodies and HCV RNA are absent or anti-HCV 
antibodies are present without HCV RNA, the occurrence 
of acute hepatitis C is very unlikely and in patients who 
have recovered from a past HCV infection, anti-HCV 
antibodies is seen in the absence of HCV RNA(Arase et 
al., 2001). Treatment of acute HCV patients with genotype 
1 is important because therapy is much more efficacious 
compared with therapy in chronic phase, so molecular 
diagnosis is critical for defining treatment responses. In 
this way the risk of major adverse effects of therapy is 
reducing with (1) optimal time after infection to initiate 
therapy (8-12 weeks); (2) treatment duration (24 weeks) 
and (3) Ribavirin is not required for optimal responses 
during acute infection (Clarysse et al., 1995; Carrión et 
al., 2009). On the other hand chronic hepatitis C is certain 
when both anti-HCV antibodies and HCV RNA are present 
and clinical signs of chronic liver disease are reported. In 
immunosupressed, hemodialysis or gammaglobulinemic 
patients HCV replication can be detectable in the absence 
of anti-HCV antibodies (Guo et al., 2012). Treatment of 
chronic HCV infections is the combination of pegylated 
interferon (IFN) alfa and Ribavirin which recommend 48 
weeks of peg-interferon plus 1000-1200 mg of ribavirin 
for genotype 1 infection and 24 weeks of peg-interferon 
plus 800 mg of Ribavirin for genotypes 2 or 3 infection 
and 24% of the patients receiving combination therapy 
achieved a rapid and sustained virological response rates 
were equivalent for 24-48 weeks of therapy using weight-
based Ribavirin (88-91%) (Vermehren et al., 2011). Thus, 
defining the treatment course for patients with genotype 
1 with rapid virological response (undetectable RNA by 
week 4) may be very useful for shortening treatment in 
individuals. Studied of genotype 2 or 3 infections reported 
that impact of shortening the treatment course is from 24 
weeks to 12-16 weeks. It is generally believed that if HCV 
RNA level develops to undetectable level after 24 weeks, 
The HCV infection has been eradicated and the patient’s 
therapy is completed. Sometimes in occult hepatitis C, 
patients have positive result for HCV antibodies but 
negative for HCV RNA with normal serum ALT levels, 
in this condition HCV RNA can be detected with low 
level in liver biopsies or peripheral blood mononuclear 
cells (Kanto et al., 1995; Ide et al., 2002; Idobe-Fujii et 
al., 2006; McCaughan et al., 2012).
Antiviral Agents 
The aim of future HCV treatment is to make antiviral 
drugs which are less toxic and allow shorter duration of 
therapy (12-24 weeks) than current standard. The HCV 
life cycle includes (1) Binding to the cell (2) uncoating (3) 
translation into a single large polyprotein (4) processing 
by cellular and viral proteases (5) RNA replication (6) 
packaging and assembly (7) Virion maturation (8) Release 
from the host cell and each of these steps can be a target 
for antiviral therapy (McCaughan et al., 2012).
Interferon and Ribavirin Therapy
Some drugs effecting on human body differently 
has been shown to have anti-viral activity against HCV. 
The first treatment against HCV was INF-α which was 
discovered in 1957. After years it has been improved 
for HCV treatment and pegylatedinterferon (PEG-INF) 
developed which has longer half-life (Buckwold et al. 
2007). Ribavirin (1-beta-D-ribofuranosyl-1, 2, 4- triazole-
3-carboxamide) is a purine-analog was discovered 30 
years ago and is effective against HCV when used with 
interferon or PEG-INF-alfa-2a in combination therapy 
and increases SVR rate. Ribavirin is not very effective in 
monotherapy and pegylated interferon (PEG-INF) and 
Ribavirin combination is a golden standard treatment 
for hepatitis C (Koev et al., 2007; Lacolla et al., 2010). 
Some mechanisms such as modulation of interferon 
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gene expression, inhibition of Inosine monophosphate 
dehydrogenase, regulation of immunity, inhibition of the 
viral RNA polymerase and lethal mutagenesis of genomes, 
caused by Ribavirin triphosphate can suppress HCV 
infection and life cycle. Unfortunately, INF and Ribavirin 
are toxic and some side effects such as headache, fever, 
severe depression, myalgia, arthralgia and haemolytic 
anaemia have been reported. In summary, development 
of cheaper and improved treatment is required and also in 
some genotypes such as 1 and 4 the response to treatment 
is weak (Ampurdanés et al., 1996; Ikejiri et al., 2007; 
Koev et al., 2007; Korba et al., 2007; Jouan et al., 2010; 
Lawitz et al., 2011).
 
NS3/4A Serine Protease Inhibitors (PIS)
NS3 protein acts as a serine protease and RNA 
helicase with its cofactor NS4A together cleave HCV 
polyprotein and help to HCV polymerase (NS5B) 
function. So NS3/4A serine protease has a vital role in 
viral replication. PI blocks NS3/4A serine protease and 
prevents viral replication (Chase et al., 2009). Two classes 
of PI molecules have been developed; (1) noncovalen 
inhibitors, such as Ciluprevir and ITMN-191/R-7227 and 
(2) covalent reversible inhibitors such as Telaprevir (TVR) 
and Boceprevir. TVR with slow binding and dissociation 
kinetics showed a reduction of viral RNA levels and 
eventually eliminated HCV RNA from the replicon cells. 
Many clinical trial studies reported that triple therapy 
(pegylated IFN, TVR, and RBV) for 12 weeks provided 
more-potent antiviral efficacy than did standard pegylated 
IFN and RBV therapy but some side effects have been 
reported. Boceprevir gained FDA approve In January 
2006, is safe and well tolerated which is more effective 
when combined with pegylated IFN. In 2003 a new 
recombinant Human antibody produced that have an 
inhibitory action on HCV helicase in carboxy terminal 
of NS3 (Chase et al., 2009; 2012; Furusyo et al., 2012).
NS5B RNA-Dependent RNA Polymerase 
Inhibitors 
HCV RNA-dependent RNA polymerase (NS5B) is an 
enzyme responsible for replication. Many antiviral drugs 
against viruses have focused on the viral polymerase and 
two types of HCV polymerase inhibitors (1) nucleoside 
analogues and (2) nonnucleoside analogues have been 
developed. The nucleoside analogue (R-1626) has potent 
antiviral activities which bind to NS5B nucleotide-binding 
site inhibits replication by acting as a chain terminator and 
stopping further elongation of RNA strand. R-1626 can 
be given together with pegylated IFN or pegylated IFN 
plus RBV to patients and no resistance mutations were 
observed but some adverse effects have been reported. 
On the other hand nonnucleoside inhibitors block the 
polymerase by interacting with outside of catalytic site. 
BMS-824 is a small molecule which binds to NS5A inhibits 
hyperphosphorylation and decreases virus replication. 
Zinc mesoporphyrin is another molecule causes NS5A 
protein downregulation by polyubiquitination and 
proteasome-dependent degradation (Wegzyn and Wyles, 
????; Zuo et al., 2007; Zhao et al., 2008; Shi et al., 2012). 
HCV Vaccines
Envelope protein vaccines
The recombinant proteins vaccine candidates induce 
an immune response to a limited number of viral epitopes 
which are cloned in bacteria, yeast or mammalian cells 
is sufficient to develop protective immunity. Some 
recombinant proteins are enough to induce immune 
response but others require adjuvant therapy (Duan et 
al., 2010). According to the genetic variability of the 
HCV viral envelope glycoprotein, this protein is the main 
target for anti-HCV antibodies. The earliest preventive 
vaccine candidate includes the envelope gpE1/gpE2 
proteins in an oil water adjuvant MF59 together with a 
CpG oligonucleotide and all cases developed neutralizing 
antibodies and T-cell lymphocyte proliferation (Frey et 
al., 2010). The first candidate therapeutic vaccine was 
a recombinant HCV-E1 protein in alum adjuvant which 
was administered to humans in 2003 and induced HCV-
specific antibody and T-cell responses in patients. In 
2003 Vaccination with HCV E1 protein (Innogenetics/
GenImmune) started with a 135aa C-terminally of 
the E1 protein formulated on alum and humoral and 
cellular immune responses were produced but failed to 
get improvement in fibrosis scores and in 2007 stopped 
(Alvarez-Obregón et al., 2001; Zeng et al., 2009).
Core proteins
Tarmogens (GlobeImmune GI-5005) are a novel 
vaccins taken up by dendritic cells and stimulate both 
innate and specific cellular immune responses are 
Core-NS3 fusion protein which expressed in yeast 
cells (Saccharomyces cervisiae) have been trialed as 
a therapeutic vaccine candidate (GI5005) and is in a 
Phase II, placebo-controlled trial and combined with 
standard therapy (PEG-IFN/ Ribavirin). Vaccinated mice 
exhibited strong Th1 with IL-2 and IFN-γ production and 
cytotoxic activity to NS3 and core proteins. Core protein 
with an adjuvant composed of Saponin, cholesterol and 
phospholipid, called ISCOMATRIX, has been evaluated in 
a Phase I trial (Alvarez-Obregón et al., 2001; Krishnadas 
et al., 2010). 
Peptide vaccines
Peptide-based vaccines induce HCV-specific T-cell 
immunity with the presentation of peptide to T-cell 
receptor by HLA molecules. IC41 (Intercell AG, Vienna, 
Austria) consists of five peptides from core, NS3 and NS4 
proteins, which are CTL epitopes (core35-44 and 132-
140, NS3 1073-1081, NS4 1764-1772) and CD4+ T cell 
epitopes (core23-44, NS3 1248-1261, NS4 1767-1786) 
combined with the adjuvant poly-l-Arginine is an example 
of peptide vaccine. In 2009, a peptide of core region 
(C35-44) was evaluated in a Phase I, dose-escalation 
in a Japanese study in 26 patients (23 nonresponders to 
PEG-IFN/Ribavirin and three who had declined standard 
therapy) (Firbas et al., 2010). In December 2006 Pevion 
Biotech started phase I clinical trial for virosome-based 
hepatitis C virus with the combination of the PeviPRO 
Hossein Keyvani et al
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and PeviTER (PEV2A and PEV2B) that utilize synthetic 
HCV peptide antigens. Synthetic lipopeptides containing 
both T helper and CD8+ epitopes induce strong T cell 
responses by increasing their uptake by antigen presenting 
cells (Firbas et al., 2006; Schlaphoff et al., 2007; Klade 
et al., 2012). 
DNA vaccines
The first DNA vaccine was licensed in 2001 and 
research efforts have been aimed an effective hepatitis 
C DNA vaccine. Several methods were developed to 
improve naked DNA delivery such as using a gene gun for 
DNA vaccination, electroporation with electrical impulses 
which creates pores in living cells and puts DNA through 
the cell membrane (Desjardins et al., 2009). The first 
DNA vaccine evaluated in Cuba in Phase I trial, which 
is (CICGB-230) combining plasmid expressing HCV 
structural antigens (core/E1/E2) with recombinant core 
protein (Co.120) (Memarnejadian and Roohvand, 2010; 
Huret et al., 2012). Another HCV DNA-based vaccine 
is a T cell vaccine based on HCV non-structural 3/4A 
which expressed under the control of the Cytomegalovirus 
immediate early promoter (ChronVac-C has recently been 
developed by TripepAB Sweden) used electroporation to 
inject plasmid expressing HCV antigens NS3/4a. CD8+ 
T cells could be eliminated against NS3/4A expressing 
hepatocytes and tumor cells in mouse model. No side 
effect was observed and two patients had viral load 
reductions of up to 1.2 and 2.4 log10 and the development 
of HCV-specific T cell reported (Ma et al., 2002; O’Hagan 
et al., 2004; Park et al., 2008; Memarnejadian and 
Roohvand, 2010).
Vector vaccines
Using viral vectors for the delivery of HCV RNA is 
the aim of vaccine choice. Adenoviral vectors are inducers 
of HCV-specific T-cell responses in the chimpanzee 
model and reduce HCV viremia during primary infection. 
Synthetic peptides are able to deliver a limited number of 
epitopes (Papa et al., 1998). However, Adenoviral vectors 
have complete viral genes, so can deliver HCV proteins 
intactly and do not be limited by HLA class restriction. 
Specific CD8+ T cell responses were induced by 
vaccination and were vital for HCV clearance of 4 of the 
5 challenged chimpanzees. Adenovirus vectors are used 
in a Phase I trial to deliver NS HCV proteins (NS3, NS4 
and NS 5B) to 36 healthy volunteers and because of pre-
existing anti-adenoviral antibodies which can limit vector 
efficacy, two Adenoviral vectors Ad6 and simian vector 
AdCh3 to which humans are rarely exposed are used and 
have been shown to induce CD4+ T cells and specific 
CD8+ T cells to make IFN-γ (Ma et al., 2002; Blanchard 
et al., 2003; Hourioux et al., 2007; Desjardins et al., 2009). 
A therapeutic vaccine (TG4040) is a recombinant poly-
antigenic T cell vaccine base on highly attenuated poxvirus 
strain, Modified vaccinia Ankara (MVA) which expresses 
NS3/4/5B proteins. Six of 15 patients received 3 weekly 
injections while the remaining 9 patients received a 4th 
injection at 6 months. T cell responses were detected in all 
patients as early as one week after the first vaccination and 
were maintained during the 6-month and the vaccination 
reduced HCV viral loads by up to 1.5 log10 (Zhang et 
al., 2008)
Future Vaccines
Virus like particles approach (VLPs)
Virus-like particles (VLPs) produced by the structural 
proteins of many viruses which have self assembly 
ability in the absence of other viral components and these 
particles (VLPs) can be isolated directly after expression 
in prokaryote and eukaryotic cells, or assembled in vitro 
from protein subunits purified from any recombinant hosts. 
VLPs recognized in the common size range of viruses 
(22–150 nm) and their exact properties depending on the 
viral proteins incorporated, but because they assemble 
without DNA or RNA or genetic materials, VLPs are 
non-infectious (Acosta-Rivero et al., 2001).
Spherical VLPs
VLPs have either helical or icosahedral symmetry 
and have a single layer of viral proteins but some VLPs 
are double-layered with outer and inner layer, whereas 
triple-layered VLPs have been recognized. They are 
models to study assembly of macromolecules and virus 
assembly (Acosta-Rivero et al., 2002). The VLP assembly 
pathway consist of protein–protein, metal ion or disulfide 
bond interactions and in some viruses, assembly can be 
mediated by proteolytic maturation. Structural proteins 
like coat proteins or capsid proteins can make VLPs, even 
in heterologous expression systems.
Expression of Norwalk virus (NV; family Caliciviridae) 
capsid protein (VP1) in insect cells showed that a 
single histidine residue at position 91 (S) domain at 
the N-terminus of VP1 can initiate VLP assembly and 
produced empty VLPs. The minor structural protein 
VP2 may be encapsidated when coexpressed in insect 
cells. This protein increases the stability of VP1 from 
disassembly and protease degradation (Acosta-Rivero 
et al., 2004).
The Adeno-associated virus 2 (family Parvoviridae) 
has VP1, VP2, and VP3 capsid proteins and only VP2, 
VP3 are necessary for capsid formation and also after 
expression in insect cells VP2 and VP3 produce VLPs 
(Chin et al., 2008).
The Rice dwarf Reovirus (RDV) contains six structural 
proteins, P1, P2, P3, P5, P7, and P8. Expression of P3 and 
P8 in insect cells, leading to VLPs formation. Double-
shelled VLPs were produced by coexpression P3 and P8 
in vitro.Sindbis alphavirus (SINV) was used to explain the 
role of a coiled coil structure. Viral capsid protein helix Ι 
has three conserved leucine residues L38, L45, and L52 
which are crucial for VLP assembly (Ait-Goughoulte et 
al., 2006).
Rod-Shaped VLPs
Two types of rod-shaped viruses are reported. The 
rigid rod-shaped in Tobamoviruses (Tobacco mosaic 
tobamovirus; TMV) and the flexible filamentous in 
Potyviruses (Johnsongrass mosaic potyvirus; JGMV).
Nonhelical native TMV and JGMV were expressed in E. 
coli (Desjardins et al., 2009).
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Viral Scaffolding Proteins
Scaffolding proteins play an essential role in correct 
assembly of the outer shell of the capsids in some viruses. 
Herpes simplex virus (family Herpesviridae) capsid have 
four outer (VP23, VP5, VP26, and VP19C) and three inner 
(VP21, VP24, and VP22a), and VP22a is a scaffolding 
protein in particle assembly. In the absence of VP23, VP5, 
or VP19C VLP assembly is not produced and lack of VP26 
has no effect on VLP formation (Thuman-Commike et al., 
1999; Newcomb et al., 2001; Fane and Prevelige, 2003).
Rotavirus is a triple-layered particle and has four 
major structural proteins VP2, VP4, VP6, and VP7 
and two minor proteins VP1 and VP3. VP2 makes 
Core like particles and its N-terminal is responsible for 
encapsidation of VP1 and VP3 (Attoui et al., 2009). An 
interaction of VP2 with VP6 is sufficient to form double-
layered VLPs. Bluetongue virus (BTV; family Reoviridae) 
has four major structural proteins VP2, VP3, VP5, VP7 
and three minor structural proteins VP1, VP4, VP6. 
Interaction between VP3 and VP7 are necessary to form 
single-shelled VLPs in a Baculovirus expression system 
(Bellamy and Both, 1990). In infectious bursa disease 
virus (family Birnaviridae), VP2 and VP3 structural 
proteins expressed in a heterologous system and showed 
that VLPs formation depends on the immature VP2 and 
C-terminal residue of VP3 (Delgui et al., 2009).
Protein–Nucleic Acid Interactions
The role of viral structural proteins is genetic material 
protection from degradation and the interaction between 
nucleic acids and VLP formation has been reported 
(Bourne et al., 2001). Hepatitis C flavivirus (HCV; family 
Flaviviridae) VLPs have been showed in the body and 
cell expression systems such as insect, bacterial, yeast. 
The first report on HCV VLPs assembly with a bilayer 
envelope indicated that 5’UTR interaction with highly 
basic N-terminal 120 or 124  amino acids of the core 
protein is necessary for VLP formation and presence of 
core, E1, E2 might enhance the assembly and formation of 
VLP process (Desjardins et al., 2009). Rous sarcoma virus 
(RSV) can assemble into VLPs in vitro in the presence of 
RNA. Some studies showed that the dimerization of Gag 
protein and nucleic acid binding domain of Gag proteins is 
crucial for formation of VLPs (Poranen and Tuma, 2004).
Cell Membranes
The formation of enveloped viruses happens by 
budding through cell membranes and two mechanisms 
can be distinguished. The first mechanism depends on 
the presence of the capsid protein which was showed in 
Retroviruses whereas Togaviruses require both capsid 
protein and envelope proteins. The second mechanism 
is called capsid independent and budding occurs by 
formation of envelopes (Blanchard et al., 2002). The 
Pr57gag precursor of Simian immunodeficiency virus and 
Gag precursor (Pr55gag) of Human immunodeficiency 
retrovirus 1 (family Retroviridae) have been expressed in 
a Baculovirus system and assembled into 100 to 120 nm 
VLPs that bud from the cell membrane and also expression 
of Gag-Pol protein by Vaccinia virus expression vector 
causes the immature and mature Retrovirus-like particles 
formation with budding from the cell surface (Affranchino 
and González, 2010). Rubella virus (family Togaviridae) 
capsid protein and the two envelope glycoproteins 
E1 and E2 form VLPs by a budding mechanism. The 
E2 transmembrane and cytoplasmic domain contains 
retention signals which are required for interaction with 
the capsid and VLP secretion (Ivanova et al., 1995).
Unlike retrovirus, members of Coronaviridae assemble 
their viral envelopes into VLPs without the capsid protein. 
The membrane glycoprotein (M) and envelope protein 
(E) are required for assembly of Coronavirus VLPs.Some 
study on VLP formation showed that M and E proteins of 
Infectious Bronchitis virus (IBV; family Coronaviridae) 
targeted to the Golgi complex need their cytoplasmic tails 
to assemble into VLPs (Liu et al., 2012).
 Influenza virus (family Orthomyxoviridae) has M1 
protein which is required to induce efficient formation 
of VLPs budding from the cell membranes and also 
human Parainfluenza virus type 1 (hPIV-1; family 
Paramyxoviridae) has matrix protein M which induced 
budding of VLPs from the plasma membrane but in 
Paramyxovirus, Simian virus 5 (SV-5) Hemagglutinin-
Neuramidase (HN) and fusion protein (F), together with 
the nucleocapsid protein (NP) are critical for VLP budding 
process (Hechtfischer et al., 1999; Barman et al., 2001; 
Fane and Prevelige, 2003). Ebola virus and Marburg 
virus (family Filoviridae) has (VP40) protein which leads 
budding and formation of filamentous spikeless VLPs by 
membrane-bound formation and corporation of the GP and 
matrix proteins in mammalian cells also cause filamentous 
formation (Lee et al., 2009).
Disulfide Bonds and Metal Ions
Disulfide bonds between interacting domains of viral 
structural proteins or ions are corresponding elements 
which leads to the VLP structure. Polyomaviruses, Murine 
polyomavirus, Simian virus 40 (SV 40), Human BK 
polyomavirus, and JC polyomavirus (JCV) have three 
proteins VP1, VP2, and VP3, of which VP1 is the major 
structural protein. Some study showed that the minor 
capsid proteins are not essential for VLP formation and 
the major structural protein VP1 forms disulfide linkages 
that stabilize dimeric and trimeric interactions. In addition 
calcium ion binding are important for assembly of the 
capsid (Chen et al., 2001). Expression of the major 
late 1 (L1) structural protein and minor late 2 (L2) 
structural protein of Human papillomavirus (HPV; family 
Papillomaviridae) in prokaryote, Baculovirus, yeast, 
or mammalian systems showed that L1 self-assembly 
produces VLP and L2 is not strictly required and disulfide 
bond formation could be essential for capsid assembly 
(Mukherjee et al., 2008).
Proteolytic Maturation
Expression of immature precursor viral envelopes 
proteins are followed by their processing seems to be an 
important strategy in formation of viral particles. The 
Thosea asigna virus (TaV; family Tetraviridae) pre-CP is 
cleaved at two positions to produce the L and S proteins 
and VLPs were formed when the cleavage between the L 
and S happens after expression (Speir and Johnson, 2008; 
Hossein Keyvani et al
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Host Factors
Beside the viral factors, the host factors and cell 
condition are important players in the efficiency of VLP 
production (Blutt et al., 2006). RSV Gag protein in insect 
cells failed to produce VLPs but the same Gag protein 
expressed in mammalian and avian cells makes VLPs 
without any modifications and it shows that chaperone in 
vertebrate cells may cause proper folding of Gag protein 
(Yoo et al., 2010). Human T-cell leukemia virus type I 
(HTLV-I) Gag and Gag-pro polyprotein show differential 
budding efficiencies. The expression of Pr53Gag 
polyprotein in Baculovirus in insect cells was unable to 
drive budding of immature VLPs (Desjardins et al., 2009). 
On the other hand, Gag particles were secreted into the 
medium as enveloped VLPs in human 293 cells. Specific 
cell factors are necessary for the maturation of the Gag 
protein and HIV VLP synthesis (Mizukoshi et al., 2009).
Principles of Virus-Like Particle-Based Vaccines
Vaccines for viral disease are attenuated or chemically 
inactivated live viruses or recombinant subunit vaccines 
with a single viral protein or peptide. Virus-like particles 
(VLPs) are a type of subunit vaccine which mimics the 
structure of virus particles and many of them completely 
lack the DNA or RNA genome. They can stimulate B-cell-
mediated immune responses and also has been shown 
that VLPs are effective at stimulating CD4 proliferative 
responses and cytotoxic T lymphocyte (CTL) responses 
(Liu et al., 2012).
Vaccines Based on VLPs
Clinical trials in humans and animal models 
 Antigens composing to VLP induce strong B cell 
as well as T cell responses. These vaccines are well 
tolerated and safe because they are noninfectious and are 
immunogenic. The immunization of young women with 
HPV16 VLPs composing major structural protein L1 
induced high titer neutralizing antibodies and protected 
the patient from HPV and reduces the incidence of 
cervical cancer and cervical dysplasia. According to this 
therapy, T-cell response increased in T-cell proliferation 
(CD4+>CD8+), Th1-(T helper 1) and Th2-specific 
cytokines(Radaelli, Bonduelle et al., 2007).
Norwalk virus (NV)-like particles tested in humans 
with oral vaccination protocol and induction of serum 
IgG in all vaccine recipients and 30-40% of the volunteers 
developed mucosal IgA (Blazevic et al., 2011). Linkage 
of adjuvant molecules to VLPs was shown to increase the 
immunogenicity of the particles. The nontoxic subunit 
B of cholera toxin (CTB) was bound to VLPs made 
specific serum IgG1, secretary IgA antibodies and cellular 
immune responses against Simian immunodeficiency 
virus Gag and Env proteins in mice. Virus like particles 
can interact with dendritic cells (DCs). In a study on 
EBOV mouse bone-marrow-derived DCs were activated 
and surface expression of CD40, CD80, CD86, major 
histocompatibility complex (MHC) class I and II and 
secretion of interleukin 6 (IL-6), IL-10, macrophage 
inflammatory protein-1a (MIP-1a) and tumor necrosis 
factors enhanced (Song et al., 2010; Hamdy et al., 2011).
Using yeast-derived HIV-1 p55gag VLPs induces 
human DCs production and makes IL-12 secretion, 
through yeast membrane-triggered Toll-like receptor 2 
signaling. These DCs can activate memory CD8+ T cells 
to become effector cells in chronically HIV-infected 
patients (Mizukoshi et al., 2009). By the ability of HBsAg 
to self-assemble into particulate structures, the particles 
were released from recombinant yeast cells allowing high-
yield production and safer purification of the vaccine. In 
the same way HIV-1 Pr55Gag polyprotein self-assembles 
into particulate spheres provided a new rationale for 
generating a Gag-based VLP vaccine and Gag is a 
common antigen expressed for vaccine approaches, and 
its VLPs can be produced in mammalian or insect cells 
and induces Th1-biased humoral and cellular immune 
responses in mice and macaques (Mizukoshi et al., 2009; 
Sistigu et al., 2011). A second class of VLPs with a wide 
range of applications is virosomes, representing virion-
like liposomebased complexes with integrated surface 
glycoproteins for endocytosis. Virosomes are becoming 
more popular since they combine with VLP and have been 
established for many viruses such as HIV, EBV and Sendai 
virus with the aim of vaccination and delivery of nucleic 
acids, drugs or heterologous antigens (Buonaguro et al., 
2007). Virus-like particles are famous as a recombinant 
protein vaccine, because they mimic the properties of 
native virions. Synthesis of HCV like particles (HCV-LPs) 
with Baculovirus which contains HCV structural proteins 
(core/E1/E2) showed that HCV-LPs have biophysical, 
ultrastructural, and antigenic properties similar to the 
native virions. In some studies BALB/c mice and HLA-A 
2.1 transgenic (AAD) mice immunized with HCV-LPs 
and strong humoral and cellular immune responses 
against HCVstructural proteins induced (Frey et al., 
2010). Furthermore, adoptive transfer of lymphocytes 
from HCV-LP-immunized mice to native mice provided 
protection against recombinant HCV-Vaccinia challenge 
in AAD mice. Adjuvants have been used with vaccines 
to elicit an immune response, and they can modulate 
different T-helper (Th1 versus Th2) response. To maximize 
HCV-LPs ability to elicit immune responses, 2 vaccine 
adjuvants tested with HCV-LPs in mice (Provided by 
Coley Pharmaceutical Group, Wellesley, MA) is an 
immunostimulatory oligodeoxynucleotide optimized for 
immune stimulation and AS01B contains monophosphoryl 
lipid A (MPL) and QS21, a naturally occurring Saponin 
molecule (Harris et al., 1996; Roohvand et al., 2007; 
Hamdy et al. 2011). The combination of HCV VLP 
and these adjuvants enhanced the speed of the immune 
responses by improving antigen presentation to T cells 
and the interaction between immunogen and macrophage 
(Qiao et al., 2003).
VLP production
The Baculovirus Expression Vector System (BEVS) 
is one of the most powerful eukaryotic expression 
systems, available to express heterologous genes from 
many different sources which has been used including 
fungi, plants, bacteria and viruses, in insect cells 
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(Futatsumori-Sugai and Tsumoto, 2010). Baculoviruses 
(family Baculoviridae) is a member of large group of 
double stranded DNA viruses which infect many different 
species of insects and its DNA (between 80 and 200 kb) is 
packaged into rod-shaped nucleocapsids. The Baculovirus 
used for VLP production is the Autographa californica 
nuclear polyhedrosis virus (AcNPV) (Roldão et al., 
2007). In this system several nonessential genes replaced 
by heterologous genes and because the Baculovirus 
genome is large to insert foreign genes, heterologous 
genes are cloned into transfer vectors. Co-transfection 
of the transfer vector and AcNPV DNA into Spodoptera 
frugiperda (Sf) cells allows recombination between 
homologous sites, transferring the heterologous gene 
from the vector to the AcNPV DNA (Lenhard et al., 
1996). With strong polyhedrin promoter (P10), AcNPV 
infection of Sf cells causing high rate of Recombinant 
proteins and VLP production produced at range between 
0.1% and 50% of the total insect cell protein. Over than 
20 years the Baculovirus–insect cell expression system 
has been used for routine production of recombinant 
proteins. This system has eukaryotic protein processing 
capabilities and insect cells can fold, modify, traffic and 
assemble polypeptides to produce products. A weak point 
of the Baculovirus expression system is its inefficiency at 
processing heterologous proteins that are synthesized as 
larger precursor proteins (Huang et al., 2002).
Baumert et al. (1998; 1999; 2000), showed that 
expression of the core, E1 and E2 proteins by recombinant 
Baculoviruses resulted in the formation of recombinant 
virus particles. These recombinant HCV particles induced 
antibodies and cell-mediated immune responses after 
immunization of rabbits. Kunkel et al. 2001 expressed 
HCV core protein in the recombinant Baculovirus 
system, and reported the generation of nucleocapsid-like 
structures. The insect cell expression system has been used 
for production of virus-like particles of papillomavirus, 
Rotavirus, human immunodeficiency virus, Norwalk 
virus, and hepatitis E virus (Baumert et al., 1999; Matsuo 
et al., 2006).
Recombinant Baculovirus (rBV) infected insect cells 
also is a useful system to investigate the viral particle 
assembly processes. For example the rBVs encoding HSV-
1 capsid proteins used to infect insect cells and purified 
capsid proteins from infected cells have been tested for 
the ability of assembling into procapsids (Belyaev et al., 
1995; Palomares et al., 2012). Human Polyomavirus JC 
virus causing progressive multifocal leukoencephalopathy 
has a major structural viral glycoprotein (VP1) which has 
been produced  recombinant VLPs with the morphology 
of empty JC virus particles by using rBVs and this 
purified VLPs are immunogenic when used with adjuvant 
(Goldmann et al., 2000; Zielonka et al., 2006). VLPs 
containing L1 structural proteins of the Human Papilloma 
Virus types 16/18 produced in Baculovirus-infected insect 
cells in clinical trials can prevent cervical infections with 
HPV-16 and HPV-18, together and block associated 
cytological abnormalities (Ault et al., 2004; de Witte et 
al., 2008). Recent studies have also showed promising 
approach for the development of an HIV/AIDS vaccine 
candidate (Tobin et al., 1995). Recently the Coronavirus 
S, E and M structural proteins of severe acute respiratory 
syndrome (SARS) have been expressed in Baculovirus-
infected insect cells and assembly of virus-like particles 
has been described and a new candidate VLP based 
vaccines against human Corona virus decease provided 
(Lai et al., 2006). 
Baculovirus transduction has been studied for 
hepatitis C virus (HCV) by placing the entire HCV cDNA 
under the control of the CMV promoter in recombinant 
Baculovirus. Transduction of HuH7 cells with rBVs-HCV 
virus expressed HCV polyprotein and processed into 
structural and non-structural gene products. HCV VLPs 
have been produced in Baculovirus–insect cell system. 
Recombinant VLPs containing HCV core, E1 and E2 
proteins have been shown to induce HCV-specific humoral 
and cellular immune responses in baboons (Scott, 2003; 
Matsuo et al., 2006; Gal-Tanamy et al., 2009). According 
to the lack of cell culture to study hepatitis B virus (HBV) 
and HCV virus, this problem was overcome by using a 
Baculovirus to deliver the HBV genome to hepatoma 
cells and produce HBV infection or deliver a cDNA copy 
of the HCV genome to cells and HCV polyprotein was 
produced and properly processed (Zeisel and Baumert, 
2006). The initial heterologous gene expression in yeast 
developed on Saccharomyces  cerevisiae which can make 
hyperglycosylate recombinant proteins and N-linked 
carbohydrate chains are terminated by a1, 3 mannose 
attached to the chain (Acosta-Rivero et al., 2001). This 
system has been applied to produce insulin and HBsAg 
of HBV virus. Alternative wide ranges of yeast-based 
systems are available: Two methylotrophic yeast species 
Hansenula polymorpha (H.p) and Pichia pastoris (P.p), 
and the two dimorphic organisms Arxula adeninivorans 
(A.a) and Yarrowia lipolytica (Y.l). Some of yeast species 
such as H. polymorpha, P. pastoris, Candida boidinii and 
P. methanolica are able to use methanol as a source of 
energy and carbon. For tow methylotrophic species (H. 
polymorpha and P. pastoris) a range of integration and 
expression vectors employ promoter elements such as 
AOX (alcohol oxidase), derived from methanol pathway 
genes. All P. pastoris strains used for heterologous gene 
expressions are from strain NRRL-Y-11430. Yeast derived 
vectors are available as circular plasmid or linearized 
and targeted to a specific genomic locus (Acosta-Rivero 
et al., 2003).
In 1970s, material and methods for supporting P. 
pastoris and the condition of growth on the methanol 
were created by Phillips Petroleum Company. In the 
early 1980s, Phillips Petroleum Company with the Salk 
Institute Biotechnology/Industrial Associates, developed 
heterologous gene expression system of P. pastoris (Falcón 
et al., 1999).
P. pastoris is a single-celled microorganism that 
is easy to manipulate and culture. The first step in 
the methanol metabolism is methanol oxidation to 
formaldehyde, generating hydrogen peroxide in the 
process by two enzyme alcohol oxidase (AOX1 and 
AOX2) but the AOX1 gene is responsible for the vast 
majority of alcohol oxidase activity in the cell (Lunsdorf 
et al., 2011). Like other eukaryotic cells, it can be able to 
make posttranslational modifications, such as proteolytic 
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processing, folding, disulfide bond formation, and O-and 
N-linked glycosylation. The length chain of glycoproteins 
expressed by P. pastoris is only 8-14 mannose residues, 
whereas that by S.cerevisiae is 40-150 residues. Thus, 
inactive proteins that are produced in bacterial systems are 
biologically active in P. pastoris. The P. pastoris system 
is faster, easier, and less expensive than other eukaryotes 
expression systems such as insect and mammalian cell 
systems. High-density fermentation of P. pastoris is vital 
for secreted proteins, so with cell density the concentration 
of culture medium be increased. Because the foreign 
genes insertion into the expression vector is carried out 
in Escherichia coli; therefore, all expression vectors of 
P. pastoris have been made as E.coli/P. pastoris shuttle 
vectors and they also have an origin of replication for 
plasmid maintenance in bacteria, with selectable markers 
for transformation of the vector in both organisms. For 
foreign proteins secretion, expression vectors have a 
secretion signal which is in frame with the foreign gene. 
E.coli is the first host for recombinant gene expression 
which has been used more than 40 years but Pichia pastoris 
within the past 15 years, has been the second most-used 
host for recombinant gene expression. From1995 to 
2009, using of P. pastoris has been increased from 4% to 
17% but in the same time usage of E. coli remained 60% 
constantly (Falcón et al., 1999; Acosta-Rivero, Aguilar 
et al., 2001; Acosta-Rivero et al., 2003; Haller, Lauer et 
al., 2007; Mizukoshi et al., 2009; Lunsdorf et al., 2011).
Yeast can secrete the protein in a form that mimics its 
native conformational structure and immunogenicity 
and in this condition the majority of antigenic epitopes 
with neutralization activity of antibodies be preserved. 
Bovine herpes virus-1 (BHV-1) gD gene, expressed in 
P. pastoris as a secretary protein while keeping its native 
conformation, can be used as a subunit vaccine against 
BHV-1. The recombinant gD protein of Equine herpes 
virus-1 (EHV-1) being expressed in P.pastoris, used in a 
boost injection program. This protein induced high EHV-1 
ELISA and virus neutralizing antibodies and also protected 
BALB/c mice which had been challenged with infection 
(Balamurugan et al., 2003; Dummer et al., 2009). L1 
protein of Human papilloma virus (HPV) type 6 expressed 
in P. pastoris, has helped the HPV vaccine development 
and structure and function study (Hanumantha et al., 
2011). The expressions of recombinant polio and Dengue 
viral vaccines in P. pastoris have also been reported. The 
recombinant envelope glycoprotein (E4) of Dengue-4 
virus produced in P. pastoris and elicited neutralizing 
antibody and haemagglutination inhibition antibodies as 
well as specific memory T cell against expressed protein 
when it was injected to BALB/c mice (Balamurugan 
et al., 2003; van Oers 2006; Roldão et al., 2011). The 
recombinant hepatitis E virus (HEV) ORF2 protein has 
been expressed in P. pastoris and high immunogenicity 
reaction against ORF2 protein was showed by inducing 
strong immune response in mice. The new fusion protein 
composing HBsAg with epitope-containing HEVAg was 
expressed in P. pastoris and this chimeric HBV/HEV virus 
like particles has been used as a recombinant HBV/HEV 
vaccine candidate (Lal et al., 1997; Patil and Khanna, 
2012).
HCV like-Particles
HCV-like particles (HCV-LP) produced by recombinant 
Baculovirus, vesicular stomatitis virus (VSV), an 
RNA replicon system of Semliki forest virus (SFV), 
and pseudotype viruses based on VSV or Retroviruses 
which have been used to examine the binding and entry 
receptors for HCV (Akazawa et al., 2011). The structural 
proteins expression by various viral vectors leads to the 
formation of virus-like particles (VLP). Its production by 
recombinant Baculovirus expression system in insect cells 
has been successful and this usage is not only for subunit 
vaccine but also for study of virus-cell interactions. 
HCV VLP based vaccine strategy makes it possible to 
elicit long lasting neutralizing antibody and core-specific 
T-cells against to vaccine construct which mimics nature 
HCV virion antigenicity. The similar investigations on 
human papilloma virus and hepatitis B virus have been 
reported (Mihailova et al., 2006). Insect cell-derived 
HCV VLPs have produced E1, E2 antigens as a Vaccine. 
These noninfectious 40-50 nm HCV-LPs consist of a lipid 
envelope containing E1 and E2. In addition Immunization 
of primates and chimpanzees with heterodimers of 
recombinant E1 and E2 proteins to stimulate a protective 
antibody response has been reported. 
HCV VLPs are superior in both mice and non-human 
primates in immunity response compared to DNA or 
recombinant envelope protein vaccines and also it is an 
advanced vaccine candidate because can induce humoral 
and cellular immunity (CTL) (T-helper) against HCV 
structural proteins and stimulate the maturation of human 
dendritic cells(Acosta-Rivero et al., 2001; 2002; 2003). 
HCV-LPs are produced by self-assembly of HCV 
structural proteins in some cells and are detected by 
morphologic, biophysical, and antigenic properties similar 
to original virions from infected humans. HCV-LPs can 
induce humoral and cellular immunity by cytotoxic and 
helper T lymphocyte cells. Dendritic cells (DCs) can 
in teract  wi th  v i ra l  par t ic les  and causes  the 
immunopathogenesis of HCV infection. Because of 
virions synthesis or purification limitation, HCV like 
particles (HCV-LPs) has been used to study HCV with 
human DCs interaction. DCs show an envelope-specific 
and binding of HCV-LPs. Some studies reported that 
C-type lectins such as DC-SIGN (DC–specific intercellular 
adhesion molecule 3-grabbing nonintegrin) were not 
enough for HCV-LP binding and this interaction followed 
by DC activation. Activated DC cells stimulate specific 
CD4 T cells by antigen processing and presentation with 
major histocompatibility complex (MHC) class II 
molecules (Kim et al., 2012; Velazquez et al., 2012). In 
insect cells, the HCV structural proteins have assembled 
into virus-like particles (HCV-LPs). The E1-E2 
heterodimer glycoprotein are presented in HCV-LPs in 
insect cells. E2 recombinant glycoprotein binds to human 
cell lines and this interaction has been used as a model for 
binding of virus to host cells. This assay showed that 
envelope glycoprotein E2 interacts with the large 
extracellular loop of cellular membrane protein CD81 as 
a receptor candidate which may play a role in T-cell 
activation (Ciccaglione et al., 1998). HCV structural 
proteins which expressed in insect cells, assembled trough 
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the large cytoplasmic cisternae into enveloped virus like 
particles (40-60 nm in diameter) derived from the 
endoplasmic reticulum (ER). Evaluation of virus like 
particles by CsCl and sucrose gradient centrifugation 
revealed biophysical information similar to natural HCV 
virions isolated from infected patients. Some study results 
suggested that HCV core and envelope proteins without 
p7 are enough for viral particle assembly and also 
production of HCV-like particles in insect cells may help 
scientists to know the structural requirements for HCV 
particle assembly as well as to study viral genome 
encapsidation and virus-host interactions (Falcón et al., 
2003). The presence of a green fluorescent protein within 
HCV pseudo-particles allowed reliable determination of 
HCV infectivity by the E1, E2 glycoproteins which are 
required for pseudo-particles infectivity and neutralized 
by sera from infected patients and anti-E2 monoclonal 
antibodies. Primary hepatocytes as well as hepato-
carcinoma cells are the major targets of infection in vitro 
and E1, E2 glycoproteins are necessary for pseudo-particle 
interaction (Katsarou et al., 2009). Recombinant 
Baculovirus are able to deliver foreign genes not only into 
insect cells, but also into mammalian cells without 
extensive cytopathic effects. Recently a modified 
recombinant Baculovirus having the VSV envelope G 
protein (VSVG) enhanced gene transfer efficacy in a 
variety of cell lines. The HCV-LP was made in a human 
hepatoma cell line, FLC4, by using the recombinant 
baculovirus system (Matsuura et al., 2001). Weijia et al. 
2010 used Pichia pastoris to express truncated HCV E1E2 
protein, which consists of E1 residues 187-346 and E2 
residues 381-699 and made high level of recombinant 
HCV E1E2 protein. The protein is glycosylated and can 
bind to the putative HCV receptor CD81 and the purified 
protein can induce anti-E1E2 antibodies in rabbits, which 
can neutralize two kinds of HCV pseudotype particles 
derived from HCV genotype 1a and 1b, as well as HCV 
virions derived from HCV genotype 2a. These findings 
indicate that the recombinant E1E2 glycoprotein is 
effective in inducing neutralizing antibodies, and is a 
potent HCV vaccine candidate (Matsuo et al., 2006; 
Kouvatsis et al., 2007). Hepatitis C virus-like particles 
(HCV-LPs) from HCV H77 strain (1a genotype) was used 
to study virus-cell interaction. HCV-LPs showed a buoyant 
density of 1.17 to 1.22 g/cm3 in a sucrose gradient and 
formed double-shelled particles 35-49 nm in diameter. 
Some results indicated that HCV-LPs can be used to 
characterize the mechanisms of early steps of HCV 
infection. With the indirect method (detection with anti-E2 
antibody) and the direct method (use of dye-labeled HCV-
LPs) showed that HCV-LPs bind to several human hepatic 
(primary hepatocytes, HepG2, HuH7, and NKNT-3) and 
T-cell (Molt-4) lines. Using anti-E1 or anti-E2 antibodies 
showed that E1 and E2 proteins mediate HCV-LPs binding 
and entry into cells. Hepatitis C virus (HCV) antigens are 
reported by transmission electron microscopy in Pichia 
pastoris. The core protein (aa 1-191) and 148 aa of the E1 
envelope antigen (aa 192-339) was cloned to express the 
first 339 NH2-terminal amino acids of the HCV 
polyprotein (C-E1.339 polypeptide) and Virus-like 
particles (VLP) with diameters ranging from 20 nm to 30 
nm were observed. The VLP stayed in the endoplasmic 
reticulum and also localized in vacuoles, either free or 
inside autophagic bodies. Chains of particles, high-density 
reticular structures, and crystalloid bodies were also 
detected. Both kinds of particles, the VLP formed after 
treatment with NP-40 and the crystal-associated particles 
were core protein-positives. Like mammalian cell lines, 
the P. pastoris yeast could be a suitable host for the analysis 
of HCV polyprotein processing and virus assembly 
(Falcón et al., 1999; Roingeard et al., 2004). HCV HCVAg 
was also recognized by serum from chronic patients. The 
electron microscopy analysis for purified HCcAg showed 
aggregated virus-like particles (VLPs) with an average 
diameter of 30 nm. The HCVAg obtained from P. pastoris 
assembled into HCV nucleocapsid like particles. Such 
HCVAg aggregates could be a valuable tool to evaluate 
the mechanisms of HCV nucleocapsid assembly. The core 
(C) protein of hepatitis C virus (HCV) is a multifunctional 
protein which is involved in many viral and cellular 
processes (Matsuo et al., 2006; Kouvatsis et al., 2007). 
Several studies have described the formation of 
nucleocapsid-like particles (NLPs) when HCV C protein 
is expressed in E. coli (Lorenzo et al., 2001), yeast 
(Acosta-Rivero et al., 2002), insect cells (Baumert et al., 
1998) or mammalian systems (Shimizu et al., 1996; 
Blanchard et al., 2002). The in vitro study developed with 
purified recombinant proteins from E. coli (Kunkel et al., 
2001) reported the first 600 nt of the HCV genome or 
structured tRNA could trigger the formation of NLPs when 
mixed with purified C protein. Also, it was shown that the 
N-terminal 120 aa of the C protein were enough for self-
assembly into particles (Baumert et al., 1999; Kunkel et 
al., 2001; Lorenzo et al., 2001; Acosta-Rivero et al., 2002; 
Roingeard et al., 2004). The in vitro assembly of several 
deleted versions of recombinant HCV C protein expressed 
in E. coli have been studied and reported that 75 
N-terminal residues of the C protein are necessary to 
assemble and generate nucleocapsid-like particles (NLPs) 
in vitro. This small protein fused to the endoplasmic 
reticulum (ER) anchoring domain also generated NLPs 
in yeast cells such as P.pastoris which had been shown 
that this yeast could be an appropriate host for the analysis 
of HCV structural polyprotein processing and nucleocapsid 
assembly. For HCV virus like other RNA viruses, 
assembly is started by the binding of the core protein to 
a unique encapsidation sequence within the viral genome, 
often a UTR with stem-loop structure. This interaction 
makes oligomerization of the core protein and virus 
particle. Some studies have been introduced new systems 
to assemble nucleocapsid-like (NCL) particles in vitro. 
More assembly studies using the Baculovirus expression 
system described that nucleic acid binding to HCVAg is 
necessary for in vitro virus like particle assembly process. 
Recently, have been illustrated that processed HCVAg 
(P21) produced in P. pastoris cells assembled into 
structured NLPs (Lorenzo et al., 2001; Acosta-Rivero et 
al., 2003; 2004; Mihailova et al., 2006).
The study of HCV assembly and morphogenesis 
have been done by HCV core protein expression with a 
Semliki Forest virus expression system and self-assembly 
into HCV-like particles (HCV-LP) at the endoplasmic 
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reticulum (ER) membrane has been reported. This system 
was used to show whether the processing of the HCV core 
protein by the signal peptide peptidase (SPP) is required 
for the HCV-LP assembly (Vidalin et al., 2000).
Conclusions
Recent research about HCV structure, genome and 
virus lifecycle showed many target sites for intervention 
and help us to improve HCV treatment. Although 
the molecular characterization of the virus has been 
investigated, many fundamental questions still remain 
unanswered. Hepatitis C virus was the first pathogenic 
human virus which has been identified by molecular 
methods. Active disease is detected by viral RNA in 
serum regardless of antibody or ALT levels and the acute 
to chronic changing is detected by HCV RNA evaluation 
6 months after exposure. Molecular diagnosis is used to 
monitor the antiviral response by measuring the presence 
and levels of virus (Cao et al., 1996). ELISAs have many 
advantages in the diagnosis such as cost-effectiveness, 
low variability and high sensitivity in screening and their 
false-positives results can be cleared by using RIBAs 
(Erensoy, 2001). INNO-LIPAs can be used to evaluate 
patient’s responses after INF therapy and also detection 
of HCV RNA by reverse transcription or PCR can be used 
for virological response to INF. According to genetic, 
geographical and etiological variations of hepatitis C virus, 
genotyping is vital to design hepatitis-related vaccines and 
biotherapeutic agents (Kamili et al., 2012).
A successful HCV vaccine is require stimulating broad 
humoral, T helper, and CTL responses. The combination of 
multiple epitopes on the HCV-LP and HCV nonstructural 
proteins can stimulate CTL and interferon responses and 
also it is necessary that it contains epitopes which are 
restricted by diverse HLA alleles. According to genetic 
heterogenicity of HCV, the vaccine should be able to 
induce cross-protective immunity against various HCV 
genotypes by using epitopes with high conserve part for 
the 6 different genotypes to induce interferon production 
and CTL response. Synthesis of peptides (i.e. 15-20 amino 
acids), can help to find immunodominant T cell epitopes 
and elicit neutralizing antibodies, or cell-mediated 
responses and antigen-driven process be enhanced by 
binding of the HCV envelope proteins to a cellular ligand 
such as CD81 (Harris et al., 1996; Nishimura et al., 1999; 
Uno-Furuta et al., 2003; Roohvand et al., 2007; Palomares-
Jerez et al., 2012). HCV infection is global health problem 
which needs effective treatment. Unfortunately there is no 
effective vaccine available for prevention and therapeutic 
options are limited especially for genotype 1. For 
genotypes 2 and 3, pegylated interferon with Ribavirin, 
can make a sustained virological response (Clarysse et 
al., 1995; Comanor et al., 2003; Albertoni et al., 2010; 
Eskander et al., 2012).
The recombinant Baculovirus system is successful in 
recombinant proteins expression such as multi-subunit 
proteins and VLPs production in insect cells. This system 
is popular in protein glycosylsation, folding, cleavage 
and secretion to enhance the yield of recombinant 
proteins produced by infected insect cells. R-BV is a tool 
for studying antigen presentation and protein-protein 
interactions and applied for the display of foreign proteins 
and epitopes on the viral surface. This new gene delivery 
has number of advantages such as superior biosafety, 
inability of virus replication, absence of cytotoxicity and 
technical simplicity. Our knowledge about Baculovirus-
cell interactions will lead future efforts to enhance vector 
design to increase transduction efficiency. The HCV-like 
particles synthesis by recombinant Baculoviruses in insect 
cells is an important tool for studying viral assembly to 
produce particles composed of fusion proteins carrying 
viral structural domains and foreign epitopes and make 
effective subunit vaccines which can mimic the virus 
particles structure without genetic material to develop 
HCV vaccine (Belyaev et al., 1995; Matsuo et al., 2006; 
Futatsumori-Sugai and Tsumoto, 2010; Palomares et al., 
2012).
P. pastoris is a powerful and standard tools used for 
recombinant protein expression. This includes the AOX1 
promoter, which is useful for regulating heterologous 
protein expression in large high density fermenter cultures. 
This methylotrophic yeast has many advantages such as 
protein processing, protein folding, and posttranslational 
modification, while being as easy to manipulate as E. coli 
or Saccharomyces cerevisiae. It is faster, easier, and less 
expensive to use than other eukaryotic expression systems 
such as Baculovirus or mammalian tissue culture, and 
generally gives higher expression levels. As yeast, it shares 
the advantages of molecular and genetic manipulations 
with Saccharomyces, and it has the added advantage of 
10-to100-fold higher heterologous protein expression 
levels (Acosta-Rivero et al., 2001; 2004). 
Virus like particles are created tools for immune 
responses induction and their development as vaccines 
or vehicles for delivering small molecules have been 
made after increasing awareness of the structure and the 
mechanism of assembly and interaction with host cells. 
They are carrying many antigens by coupling with them 
and become vaccines tools for disease prevention and 
therapy. This novel class of subunit vaccine is able to 
induce efficient cellular and humoral immune responses 
for both viral and non-viral diseases. VLPs are safer than 
many live viruses because they are free of viral genetic 
material and more effective than many subunit vaccines 
because of their conformational properties. HCV-like 
particles synthesis without the nonstructural genes 
required for viral replication can be an excellent Candida 
for HCV vaccine production. VLPs structure characterized 
by X-ray crystallography and advanced EM techniques 
and focuses on the comparison of VLPs composed of 
different numbers and combinations of structural proteins 
(Lal et al., 1997; Falcón et al., 1999; Acosta-Rivero et al., 
2003; Balamurugan et al., 2003; Lunsdorf et al., 2011; 
Patil and Khanna, 2012).
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